<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688415</url>
  </required_header>
  <id_info>
    <org_study_id>VRXP-A101</org_study_id>
    <nct_id>NCT00688415</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer</brief_title>
  <official_title>A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <brief_summary>
    <textblock>
      This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may&#xD;
      stimulate the immune system to help fight cancer. The purpose of the study is to assess the&#xD;
      safety of the investigational drug and to identify the highest dose that is well-tolerated.&#xD;
      The pharmacology of VTX-2337 will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and identification of dose-limiting toxicities</measure>
    <time_frame>Study duration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>First dose of investigational drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of the MTD</measure>
    <time_frame>First cycle of investigational drug</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VTX-2337</intervention_name>
    <description>Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Other specific eligibility criteria may apply. Examination by the investigator is necessary&#xD;
        to fully determine eligibility.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability and willingness to provide written informed consent&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumors or lymphoma&#xD;
&#xD;
          -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Life expectancy of at least 16 weeks&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Acceptable physical exam and laboratory tests at study entry&#xD;
&#xD;
          -  Willingness to use medically acceptable contraception&#xD;
&#xD;
          -  A negative serum pregnancy test for women with reproductive potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anticancer therapy within 2 weeks&#xD;
&#xD;
          -  Treatment with an investigational agent within 4 weeks&#xD;
&#xD;
          -  Systemic corticosteroids within 2 weeks or a requirement for systemic&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Known brain metastases unless stable for at least 28 days&#xD;
&#xD;
          -  Active autoimmune disease&#xD;
&#xD;
          -  Insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  Clinically significant cardiac disease within 6 months&#xD;
&#xD;
          -  Significant infection or fever within 1 week&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Other conditions or circumstances that could interfere with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar Patel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

